TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27608764

Group type: EXPERIMENTAL
Intervention: Alcohol use disorder
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Control group (no alcohol use disorder)
Number of subjects: 1388
Study: 27609188

Group type: EXPERIMENTAL
Intervention: Tidal volume of 6 ml/kg
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Tidal volume of 8 ml/kg
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Tidal volume of 10 ml/kg
Number of subjects: 69
Study: 27609252

Group type: EXPERIMENTAL
Intervention: +CTO
Number of subjects: 675

Group type: COMPARATOR
Intervention: -CTO
Number of subjects: 675
Study: 27609256

Group type: EXPERIMENTAL
Intervention: Transaortic access for TAVR
Number of subjects: 301
Study: 27609682

Group type: EXPERIMENTAL
Intervention: New-generation devices (Sapien 3 and Lotus)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Early-generation devices (Sapien XT and CoreValve)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: New-generation devices
Number of subjects: 301

Group type: COMPARATOR
Intervention: Early-generation devices
Number of subjects: 301
Study: 27609689

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillators for primary prevention
Number of subjects: 0
Study: 27609778

Group type: EXPERIMENTAL
Intervention: Per-oral endoscopic myotomy (POEM)
Number of subjects: 241
Study: 27609817

Group type: EXPERIMENTAL
Intervention: (13)N-ammonia positron emission tomography (13NH3-PET)
Number of subjects: 130
Study: 27611192

Group type: EXPERIMENTAL
Intervention: Plant stanol enriched margarine (3 g/d plant stanols)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Plant sterol enriched margarine (3 g/d plant sterols)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control margarine (no addition)
Number of subjects: 42
Study: 27611967

Group type: EXPERIMENTAL
Intervention: Panchakarma-based Ayurvedic intervention
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 27612149

Group type: EXPERIMENTAL
Intervention: Ingenol mebutate 0.05% gel
Number of subjects: 26
Study: 27612457

Group type: EXPERIMENTAL
Intervention: Mean 6-item score according to Giangreco
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Neurological findings
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Seizures
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Anxiety disorders
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ADHD/ADD
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Impairment of social behavior
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Other comorbidities
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Mean Aberrant Behaviour Checklist Community Edition (ABC-C) score
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Mean visual analogue scale (VAS) score
Number of subjects: 75
Study: 27612488

Group type: EXPERIMENTAL
Intervention: Chromoendoscopy (CE) with 0.4% indigo carmine
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Chromoendoscopy (CE)
Number of subjects: 350
Study: 27612875

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Score (MDS)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Baltic Sea Diet Score (BSDS)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Finnish Children Healthy Eating Index (FCHEI)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Highest third of BSDS and FCHEI
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Diet scores (MDS, BSDS, FCHEI)
Number of subjects: 161
Study: 27612924

Group type: EXPERIMENTAL
Intervention: Per-oral endoscopic tunneling for restoration of the esophagus (POETRE)
Number of subjects: 4
Study: 27612987

Group type: EXPERIMENTAL
Intervention: High-dose melphalan followed by autologous hematopoietic stem cell transplantation
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Induction therapy (bortezomib-based in combination with dexamethasone and either thalidomide, cyclophosphamide or lenalidomide) for 4-6 cycles
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells collected after high-dose cyclophosphamide plus G-CSF or G-CSF alone
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Melphalan at 140 mg/m² as conditioning regimen
Number of subjects: 56
Study: 27613072

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV) lot released between August 1 and September 15, 2013
Number of subjects: 0

Group type: COMPARATOR
Intervention: Live attenuated influenza vaccine (LAIV) lot shipped earlier or later than August 1 to September 15, 2013
Number of subjects: 0

Group type: COMPARATOR
Intervention: LAIV (trivalent or quadrivalent formulations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LAIV against A/H3N2 and B strains
Number of subjects: 0
Study: 27613189

Group type: EXPERIMENTAL
Intervention: L-DEP regimen (PEG-aspargase and modified DEP regimen)
Number of subjects: 28
Study: 27614001

Group type: EXPERIMENTAL
Intervention: Implantation of pacemaker or defibrillator
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Age at diagnosis < 46 years
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Mycophenolate treatment
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: LVEF > 40%
Number of subjects: 73

Group type: COMPARATOR
Intervention: Age ≥ 46 years
Number of subjects: 73

Group type: COMPARATOR
Intervention: Lack of implanted pacemaker or defibrillator
Number of subjects: 73

Group type: COMPARATOR
Intervention: Reduced LVEF < 40%
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Transplant or death from sarcoidosis
Number of subjects: 73
Study: 27614379

Group type: EXPERIMENTAL
Intervention: Edwards Sapien 3 valve (ES3)
Number of subjects: 200
Study: 27614912

Group type: EXPERIMENTAL
Intervention: [(14)C]prucalopride succinate 2 mg (~200 nCi)
Number of subjects: 6
Study: 27616471

Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV7+DTaP (concomitant)
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTaP alone
Number of subjects: 0
Study: 27616553

Group type: EXPERIMENTAL
Intervention: Ibrutinib (560 mg once daily; 28-day cycle)
Number of subjects: 16
Study: 27617031

Group type: EXPERIMENTAL
Intervention: Children from low-income families
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sedentary lifestyle and unhealthy eating habits
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Healthcare professionals' interventions
Number of subjects: 42
Study: 27617496

Group type: EXPERIMENTAL
Intervention: Interferon-based therapy
Number of subjects: 10
Study: 27617637

Group type: EXPERIMENTAL
Intervention: Targeted cognitive training (TCT) of the auditory system, 40 hours duration.
Number of subjects: 131
Study: 27618501

Group type: EXPERIMENTAL
Intervention: Once-daily degludec
Number of subjects: 29
Study: 27618681

Group type: EXPERIMENTAL
Intervention: Objective criteria for identifying patients with OHCA with no chance of survival (not witnessed by emergency medical services, nonshockable initial cardiac rhythm, no return of spontaneous circulation before a third 1-mg dose of epinephrine)
Number of subjects: 6963

Group type: EXPERIMENTAL
Intervention: Objective criteria for identifying patients with OHCA with no chance of survival
Number of subjects: 6963
Study: 27619225

Group type: EXPERIMENTAL
Intervention: 2 trabecular micro-bypass stents
Number of subjects: 101

Group type: COMPARATOR
Intervention: Topical travoprost
Number of subjects: 101
Study: 27619774

Group type: EXPERIMENTAL
Intervention: Eeva Test plus standard morphology
Number of subjects: 280

Group type: COMPARATOR
Intervention: Propensity matched control group (morphology only)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Eeva High and Medium embryos
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Eeva Low embryos
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Eeva Test group
Number of subjects: 280

Group type: COMPARATOR
Intervention: Propensity matched control group
Number of subjects: 280
Study: 27619954

Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment
Number of subjects: 43
Study: 27621400

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg/d continuously until disease progression or unacceptable toxicity
Number of subjects: 26
Study: 27621408

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus Palifosfamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxorubicin plus Placebo
Number of subjects: 0
Study: 27621833

Group type: EXPERIMENTAL
Intervention: Low eosinophil counts (<0.05 compared with 0.15-0.25×10(9)/L)
Number of subjects: 775231

Group type: EXPERIMENTAL
Intervention: Low lymphocyte counts (<1.45 vs 1.85-2.15×10(9)/L)
Number of subjects: 775231
Study: 27622077

Group type: EXPERIMENTAL
Intervention: MEDI9447
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of MEDI9447 and anti-PD-1 antibodies
Number of subjects: 0
Study: 27622157

Group type: EXPERIMENTAL
Intervention: SBRT 35 Gy
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: SBRT 40 Gy
Number of subjects: 114
Study: 27622162

Group type: EXPERIMENTAL
Intervention: Rotavirus-positive children
Number of subjects: 624

Group type: COMPARATOR
Intervention: Rotavirus-negative children
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Overall RVGE cases
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Hospitalization of AGE cases
Number of subjects: 624
Study: 27622858

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400mg/day) + Daclatasvir (60mg/day) for 12 weeks
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400mg/day) + Daclatasvir (60mg/day) for 24 weeks
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400mg/day) + Daclatasvir (60mg/day) + Ribavirin (1-1.2g/day) for 24 weeks
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400mg/day) + Daclatasvir (60mg/day) + Ribavirin (1-1.2g/day) for 12 weeks
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400mg/day) + Daclatasvir (60mg/day) in non-cirrhotic patients
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400mg/day) + Daclatasvir (60mg/day) in cirrhotic patients for 12 weeks
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400mg/day) + Daclatasvir (60mg/day) in cirrhotic patients for 24 weeks
Number of subjects: 768
Study: 27623532

Group type: EXPERIMENTAL
Intervention: Task-oriented training with interactive computer games and objects of daily life
Number of subjects: 30

Group type: COMPARATOR
Intervention: Finger mobility and strengthening exercises
Number of subjects: 30
Study: 27624138

Group type: EXPERIMENTAL
Intervention: Glycated albumin
Number of subjects: 236

Group type: COMPARATOR
Intervention: Hemoglobin A1c
Number of subjects: 236
Study: 27624355

Group type: EXPERIMENTAL
Intervention: No PPM group
Number of subjects: 183

Group type: COMPARATOR
Intervention: PPM group
Number of subjects: 183
Study: 27624417

Group type: EXPERIMENTAL
Intervention: Anxious depression group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nonanxious depression group
Number of subjects: 28
Study: 27624549

Group type: EXPERIMENTAL
Intervention: Decitabine at 20 mg/m²
Number of subjects: 0
Study: 27624571

Group type: EXPERIMENTAL
Intervention: ESBL-producing Escherichia coli (ESBL-EC)
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: ESBL-producing Klebsiella pneumoniae (ESBL-KP)
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Healthcare-associated infections, obstructive urinary tract disease, previous surgical history, and use of a cephalosporin antibiotic within 3 months
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 919
Study: 27624579

Group type: EXPERIMENTAL
Intervention: Hyperglycemic clamp (225 and 400 mg/dl) followed by IV arginine bolus
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fasting IAPP concentrations
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Basal IAPP secretion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IAPP/C-peptide ratio
Number of subjects: 40
Study: 27624592

Group type: EXPERIMENTAL
Intervention: Diastolic function grade (DFG) assessment
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Ventricular morphology
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Maximal effort on exercise testing
Number of subjects: 546
Study: 27624746

Group type: EXPERIMENTAL
Intervention: Distributed Parameter (DP) modeling
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fermi modeling
Number of subjects: 24

Group type: COMPARATOR
Intervention: Visual assessments
Number of subjects: 24
Study: 27624877

Group type: EXPERIMENTAL
Intervention: Personalized visualization of cardiovascular risk levels through a website and group consultation with a nurse
Number of subjects: 600
Study: 27625344

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q4W
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg Q2W
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 27625358

Group type: EXPERIMENTAL
Intervention: HLA allele-matched unrelated donor transplant with conditioning regimen including alemtuzumab, fludarabine, and melphalan; GVHD prophylaxis with calcineurin inhibitor, short-course methotrexate, and methylprednisolone.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HLA allele-matched unrelated donor transplant
Number of subjects: 30
Study: 27627050

Group type: EXPERIMENTAL
Intervention: Nintedanib (150 mg for mild impairment, 100 mg for moderate impairment, escalating to 200 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 30
Study: 27627808

Group type: EXPERIMENTAL
Intervention: ARQ 087
Number of subjects: 0
Study: 27627818

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 120
Study: 27627987

Group type: EXPERIMENTAL
Intervention: Genetic variants in VEGF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27628064

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 12
Study: 27628323

Group type: EXPERIMENTAL
Intervention: JE-CV booster dose
Number of subjects: 50
Study: 27628523

Group type: EXPERIMENTAL
Intervention: Simtomax
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: IgA-TTG
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: EMA
Number of subjects: 934
Study: 27629052

Group type: EXPERIMENTAL
Intervention: Carriers of the minor C allele at the PLIN1 6209T>C variant
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: AA carriers eating late
Number of subjects: 1287

Group type: COMPARATOR
Intervention: TT carriers
Number of subjects: 1287
Study: 27629486

Group type: EXPERIMENTAL
Intervention: IL-6 stimulation in T cells from individuals with T1D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-6 stimulation in CD4(+) T cells from patients with T1D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-6-targeted therapeutic intervention (currently being tested, NCT02293837)
Number of subjects: 0
Study: 27629548

Group type: EXPERIMENTAL
Intervention: Intensive multidisciplinary team intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidisciplinary interventions
Number of subjects: 0
Study: 27629938

Group type: EXPERIMENTAL
Intervention: Pediatric Sleep Questionnaire (PSQ)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sagittal abdominal diameter
Number of subjects: 45
Study: 27630075

Group type: EXPERIMENTAL
Intervention: Autism Spectrum Disorder (ASD)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Attention Deficit Hyperactivity Disorder (ADHD)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy male controls
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ASD
Number of subjects: 23
Study: 27630340

Group type: EXPERIMENTAL
Intervention: Indocyanine green fluorescence imaging (ICG-FI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Patent blue (PB)
Number of subjects: 20
Study: 27630572

Group type: EXPERIMENTAL
Intervention: Daily consumption of five or more medicinal molecules
Number of subjects: 113
Study: 27631025

Group type: EXPERIMENTAL
Intervention: lasR mutant strains of Pseudomonas aeruginosa
Number of subjects: 101

Group type: COMPARATOR
Intervention: LasR-intact strains of Pseudomonas aeruginosa
Number of subjects: 101
Study: 27631092

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25OHD) levels below identified cut-points
Number of subjects: 344

Group type: COMPARATOR
Intervention: Serum 25-hydroxyvitamin D (25OHD) levels above identified cut-points
Number of subjects: 344
Study: 27631751

Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance (TJQMBB) program
Number of subjects: 36
Study: 27632289

Group type: EXPERIMENTAL
Intervention: HER2-targeted therapy (trastuzumab/pertuzumab)
Number of subjects: 226

Group type: COMPARATOR
Intervention: PRO Onc assay
Number of subjects: 226
Study: 27632680

Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor-modified T cell therapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Tocilizumab (interleukin-6 receptor antibody)
Number of subjects: 39
Study: 27632776

Group type: EXPERIMENTAL
Intervention: Excess gestational weight gain (GWG)
Number of subjects: 40
Study: 27633122

Group type: EXPERIMENTAL
Intervention: Sandoz biosimilar filgrastim, administered twice daily
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Sandoz biosimilar filgrastim
Number of subjects: 245
Study: 27633375

Group type: EXPERIMENTAL
Intervention: Higher tertile of TyG index
Number of subjects: 888

Group type: COMPARATOR
Intervention: Lower tertile of TyG index
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Highest tertile of TyG index
Number of subjects: 888
Study: 27633393

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) of atrial fibrillation (AF)
Number of subjects: 192
Study: 27633513

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.01%
Number of subjects: 312
Study: 27633639

Group type: EXPERIMENTAL
Intervention: Upper body progressive resistance training and diet counselling to correct deficiencies in nutrient intake plus counselling on caloric restriction and aerobic exercise to achieve a weight loss of 0.68-0.919 kg/week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Upper body progressive resistance training and diet counselling to correct deficiencies in nutrient intake
Number of subjects: 40
Study: 27634203

Group type: EXPERIMENTAL
Intervention: Momelotinib 200 mg twice daily
Number of subjects: 61
Study: 27634566

Group type: EXPERIMENTAL
Intervention: Pazopanib at 800 mg oral daily until disease progression
Number of subjects: 17
Study: 27635072

Group type: EXPERIMENTAL
Intervention: Extensive cardiac workup including ECG, signal averaged ECG, exercise testing, cardiac imaging, Holter-monitoring, and selective provocative drug testing with epinephrine or procainamide
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Genetic testing performed when a mutation was identified or phenotype suggestive of inherited arrhythmia syndrome
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Systematic cascade screening and genetic testing
Number of subjects: 398
Study: 27635086

Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C Metabolic MRI
Number of subjects: 4

Group type: COMPARATOR
Intervention: Conventional proton cardiac magnetic resonance imaging
Number of subjects: 4
Study: 27635623

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) delivered in 5 fractions to a dose of 25 to 40 Gy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 11
Study: 27636157

Group type: EXPERIMENTAL
Intervention: Probable PTSD
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Heavy drinking
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Cocaine use
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Partner physical violence
Number of subjects: 810
Study: 27636400

Group type: EXPERIMENTAL
Intervention: FLARE-RA self-administered questionnaire
Number of subjects: 138
Study: 27636672

Group type: EXPERIMENTAL
Intervention: Higher education (proxy for cognitive reserve)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High WMH volume among highly educated participants
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low WMH volume among highly educated participants
Number of subjects: 90
Study: 27636722

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 53
Study: 27637014

Group type: EXPERIMENTAL
Intervention: Inhibin B (INHB) <50 ng/dL
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Low INHB
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Total testosterone (TT)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Anti-mullerian hormone (AMH)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sertoli cell dysfunction
Number of subjects: 93
Study: 27637340

Group type: EXPERIMENTAL
Intervention: 800mg DHA/day during pregnancy (DOMInO trial)
Number of subjects: 300000

Group type: EXPERIMENTAL
Intervention: 600mg DHA/day during pregnancy (KUDOS trial)
Number of subjects: 300000

Group type: COMPARATOR
Intervention: Placebo during pregnancy (both trials)
Number of subjects: 300000
Study: 27637428

Group type: EXPERIMENTAL
Intervention: Romidepsin at 14 mg/m²
Number of subjects: 30
Study: 27637497

Group type: EXPERIMENTAL
Intervention: Livelihood intervention (microfinance loan, agricultural and financial training, human-powered water pump)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Livelihood intervention
Number of subjects: 117
Study: 27637985

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg orally once daily until progressive disease or unacceptable toxicity
Number of subjects: 144
Study: 27639327

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 831

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 831
Study: 27640066

Group type: EXPERIMENTAL
Intervention: Supracervical hysterectomy
Number of subjects: 212

Group type: COMPARATOR
Intervention: Total abdominal hysterectomy
Number of subjects: 212
Study: 27641497

Group type: EXPERIMENTAL
Intervention: Back on Track intervention (biopsychosocial primary care intervention)
Number of subjects: 0
Study: 27641687

Group type: EXPERIMENTAL
Intervention: CRISPR-Cas9 genome editing technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRISPR-Cas9
Number of subjects: 0
Study: 27641715

Group type: EXPERIMENTAL
Intervention: Surgical release of tongue-tie/lip-tie
Number of subjects: 237

Group type: COMPARATOR
Intervention: Preoperative breastfeeding measures
Number of subjects: 237
Study: 27642132

Group type: EXPERIMENTAL
Intervention: MenACWY-D (0.5-mL booster dose)
Number of subjects: 834